Back

GLP1 receptor agonism attenuates anthracycline and HER2 targeted therapy induced cardiac dysfunction and systemic inflammation in non-diabetic models

19 June 2026 (15:30 - 16:15)
Organised by: Logo
Congress Presentation Part of: Heart failure and cancer therapy–related cardiac dysfunction: phenotypes, mechanisms and cardioprotection Cardio-Oncology Delegates Premium Access ESC Cardio-Oncology 2026 Council of Cardio-Oncology

About the speaker

Photo
Doctor Vincenzo Quagliariello

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

4 More presentations in this session

Presentation thumbnail
What is the incidence of heart failure with preserved ejection fraction (HFpEF) versus heart failure with reduced ejection fraction (HFrEF) in breast cancer survivors compared to non-cancer controls?
Mr A. Bolad (Zionsville, US)
Abstract Slides
Presentation thumbnail
The cardiac phenotype of treatment naive patients with early breast cancer: a precursor to HFpEF?
Doctor I. Paterson (Ottawa, CA)
Abstract Slides
Presentation thumbnail
History of cancer and clinical outcomes in patients with recurrent acute heart failure; sub-analysis of the SAVIOR-L study
Professor Y. Fukumoto (Kurume, JP)
Abstract Slides
Presentation thumbnail
A circulating biotarget in breast-tumor-bearing mice suffering from chemotherapy-induced cardiac dysfunction
Doctor H. Nordin (Paris, FR)
Abstract Slides

Access the full session

Session thumbnail
Heart failure and cancer therapy–related cardiac dysfunction: phenotypes, mechanisms and cardioprotection

The Event

Event poster

ESC Cardio-Oncology 2026

19 June 2026 15:30 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources